Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GB Group plc stock logo
GBGPF
GB Group
$3.15
$3.11
$3.15
$3.15
N/AN/A500 shsN/A
HWH
HWH International
$2.05
+23.5%
$1.22
$0.75
$15.04
$33.24M-0.61719,217 shs7.49 million shs
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$74.46
+0.6%
$74.21
$53.12
$77.72
$12.43B0.58193,138 shs60,642 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GB Group plc stock logo
GBGPF
GB Group
0.00%0.00%0.00%+5.00%-19.79%
HWH
HWH International
-5.68%+62.75%+74.74%+9.21%+165,999,900.00%
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
+4.36%+4.37%+1.68%+6.44%+24.47%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GB Group plc stock logo
GBGPF
GB Group
N/AN/AN/AN/AN/AN/AN/AN/A
HWH
HWH International
N/AN/AN/AN/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
0.6841 of 5 stars
1.03.01.70.01.60.01.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GB Group plc stock logo
GBGPF
GB Group
N/AN/AN/AN/A
HWH
HWH International
N/AN/AN/AN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
2.00
Hold$80.007.44% Upside

Current Analyst Ratings

Latest RDY, FGO, GBGPF, and HWH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
1/29/2024
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$75.00 ➝ $80.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GB Group plc stock logo
GBGPF
GB Group
N/AN/AN/AN/AN/AN/A
HWH
HWH International
N/AN/A$0.24 per share8.43($0.90) per shareN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$2.99B4.15$4.42 per share16.83$16.87 per share4.41

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GB Group plc stock logo
GBGPF
GB Group
N/AN/A0.00N/AN/AN/AN/AN/A
HWH
HWH International
$550KN/A0.00N/AN/A-27.08%1.41%N/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$548M$3.7919.6518.071.7719.26%20.97%15.19%5/8/2024 (Estimated)

Latest RDY, FGO, GBGPF, and HWH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
1/31/202412/31/2023
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$0.88$0.99+$0.11$0.99$827.81 million$867.00 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GB Group plc stock logo
GBGPF
GB Group
N/AN/AN/AN/AN/A
HWH
HWH International
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$0.410.55%+13.13%10.82%4 Years

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GB Group plc stock logo
GBGPF
GB Group
N/AN/AN/A
HWH
HWH International
N/A
0.84
0.84
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
0.02
2.55
1.90

Ownership

Institutional Ownership

CompanyInstitutional Ownership
GB Group plc stock logo
GBGPF
GB Group
N/A
HWH
HWH International
25.66%
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
14.02%

Insider Ownership

CompanyInsider Ownership
GB Group plc stock logo
GBGPF
GB Group
N/A
HWH
HWH International
61.50%
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
2.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
GB Group plc stock logo
GBGPF
GB Group
1,183N/AN/ANot Optionable
HWH
HWH International
N/A16.22 million6.25 millionN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
25,863166.88 million163.54 millionOptionable

RDY, FGO, GBGPF, and HWH Headlines

SourceHeadline
Dr. Reddys Laboratories (NYSE:RDY) Shares Gap Up to $70.92Dr. Reddy's Laboratories (NYSE:RDY) Shares Gap Up to $70.92
marketbeat.com - April 25 at 4:49 PM
Dr. Reddy’s Issues Voluntary Nationwide Recall of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg Due to Sub-PotencyDr. Reddy’s Issues Voluntary Nationwide Recall of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg Due to Sub-Potency
usatoday.com - April 23 at 2:57 PM
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
zacks.com - April 18 at 12:16 PM
Dr. Reddys Laboratories Limited to Post FY2026 Earnings of $4.11 Per Share, Zacks Research Forecasts (NYSE:RDY)Dr. Reddy's Laboratories Limited to Post FY2026 Earnings of $4.11 Per Share, Zacks Research Forecasts (NYSE:RDY)
americanbankingnews.com - April 18 at 2:26 AM
Research Analysts Set Expectations for Dr. Reddys Laboratories Limiteds FY2026 Earnings (NYSE:RDY)Research Analysts Set Expectations for Dr. Reddy's Laboratories Limited's FY2026 Earnings (NYSE:RDY)
marketbeat.com - April 17 at 6:35 PM
Dr Reddys launches migraine management device in EuropeDr Reddy's launches migraine management device in Europe
devdiscourse.com - April 10 at 10:21 AM
Vanguard Group Inc. Grows Stake in Dr. Reddys Laboratories Limited (NYSE:RDY)Vanguard Group Inc. Grows Stake in Dr. Reddy's Laboratories Limited (NYSE:RDY)
marketbeat.com - April 7 at 4:10 AM
Dr. Reddys Laboratories (NYSE:RDY) Upgraded to Strong-Buy by StockNews.comDr. Reddy's Laboratories (NYSE:RDY) Upgraded to Strong-Buy by StockNews.com
marketbeat.com - April 5 at 11:10 PM
Assenagon Asset Management S.A. Has $13.65 Million Stock Holdings in Dr. Reddys Laboratories Limited (NYSE:RDY)Assenagon Asset Management S.A. Has $13.65 Million Stock Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)
marketbeat.com - March 29 at 5:16 AM
Pharmazz Inc. and Dr. Reddys Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in IndiaPharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
finance.yahoo.com - March 22 at 10:02 AM
Heres Why Doctor Reddys (RDY) is a Strong Value StockHere's Why Doctor Reddy's (RDY) is a Strong Value Stock
zacks.com - March 20 at 10:41 AM
Dr. Reddys Laboratories launches Versavo® (bevacizumab) in the UKDr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
businesswire.com - March 19 at 7:00 AM
Why Doctor Reddys (RDY) is a Top Value Stock for the Long-TermWhy Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
zacks.com - February 28 at 10:41 AM
Dr. Reddys Laboratories Limited - Depositary Receipt () (RDY) Price Target Increased by 5.17% to 71.72Dr. Reddy's Laboratories Limited - Depositary Receipt () (RDY) Price Target Increased by 5.17% to 71.72
msn.com - February 24 at 3:03 PM
Heres Why Doctor Reddys (RDY) is a Strong Momentum StockHere's Why Doctor Reddy's (RDY) is a Strong Momentum Stock
zacks.com - February 23 at 10:56 AM
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising DemandGlobal Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
msn.com - February 22 at 8:07 PM
Novo to face Wegovy competition in India as local versions loom: ReutersNovo to face Wegovy competition in India as local versions loom: Reuters
msn.com - February 22 at 12:58 PM
Why Doctor Reddys (RDY) is a Top Growth Stock for the Long-TermWhy Doctor Reddy's (RDY) is a Top Growth Stock for the Long-Term
zacks.com - February 22 at 10:51 AM
RDY Jun 2024 60.000 callRDY Jun 2024 60.000 call
ca.finance.yahoo.com - February 6 at 8:54 PM
Dr. Reddys (RDY) Q3 Earnings and Revenues Surpass EstimatesDr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates
finance.yahoo.com - February 1 at 12:38 PM
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call TranscriptDr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call Transcript
finance.yahoo.com - February 1 at 12:38 PM
Teva hits 52-week high on outlook, API divestmentTeva hits 52-week high on outlook, API divestment
msn.com - January 31 at 4:08 PM
UPDATE 1-Indian pharma firm Dr Reddys beats Q3 profit view on strong US, European businessesUPDATE 1-Indian pharma firm Dr Reddy's beats Q3 profit view on strong US, European businesses
finance.yahoo.com - January 31 at 4:08 PM
Dr. Reddy’s Q3 & 9M FY24 Financial ResultsDr. Reddy’s Q3 & 9M FY24 Financial Results
finance.yahoo.com - January 31 at 4:08 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

GB Group logo

GB Group

OTCMKTS:GBGPF
GB Group plc, together with its subsidiaries, provides digital identity products and services in the United Kingdom, the United States of America, Australia, and internationally. The company operates through three segments: Location, Identity, and Fraud. It provides identity products comprising ID3global, an identity verification, IDscan, a ID document verification, IDscan core, a personalized document verification, Scannet, a venue ID verification, investigate, a search subject analysis, and ProID, a no-code industry verification solution. In addition, the company offers location data products, which includes Address Capture, a real-time global address look-up, Address Verify, an address data parsing, standardizing, and cleansing solution, Data Cleanse, a data validation, and deduping, suppressing, and screening solution, as well as bank verification, geocode, and email verification solutions. Further, it provides fraud and compliance products including Predator, a transaction and anti-money laundering solution; and Instinct, a fraud risk management platform, as well as mobile intelligence, which uses mobile data to enable identity verification and fraud prevention. The company serves banking, financial services and fintech, gaming, nightclubs, crypto and FX, pensions, retail and ecommerce, and insurance industries. GB Group plc was formerly known as Telme Group plc and changed its name to GB Group plc in February 2002. The company was incorporated in 1989 and is based in Chester, the United Kingdom.

HWH International

NASDAQ:HWH
HWH International Inc. operates a marketplace to provide products and services for health, wealth, and happiness. The company operates through HWH Marketplace, Hapi Cafés, Hapi Travel, and Hapi Wealth Builder segments. The HWH Marketplace segment provides products manufactured by its affiliate companies at a discounted price to its members. The Hapi Cafés segment operates Hapi Cafe branded outlets in Asia, including Singapore, Republic of China (Taiwan), Hong Kong, the People's Republic of China, and South Korea. The Hapi Travel segment offers vacation packages, hotels, cruises, and other travel products for HWH members. The Hapi Wealth Builder segment focuses on exploring the options of providing services to its members through financial educational materials. The company is based in Bethesda, Maryland. HWH International Inc. operates as a subsidiary of Alset International Limited.
Dr. Reddy

Dr. Reddy's Laboratories

NYSE:RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.